Page last updated: 2024-09-03

vasotocin, 1-(beta-mercapto-(beta, beta-cyclopentamethylene)propionic acid)-tyr(om3)(2)-orn(8)- and Substance Withdrawal Syndrome

vasotocin, 1-(beta-mercapto-(beta, beta-cyclopentamethylene)propionic acid)-tyr(om3)(2)-orn(8)- has been researched along with Substance Withdrawal Syndrome in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
He, C; Li, JH; Lu, CL; Song, CY; You, ZD1

Other Studies

1 other study(ies) available for vasotocin, 1-(beta-mercapto-(beta, beta-cyclopentamethylene)propionic acid)-tyr(om3)(2)-orn(8)- and Substance Withdrawal Syndrome

ArticleYear
Oxytocin mediates the inhibitory action of acute lithium on the morphine dependence in rats.
    Neuroscience research, 2001, Volume: 41, Issue:2

    Topics: Analgesics, Opioid; Animals; Antimanic Agents; Behavior, Animal; Conditioning, Psychological; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Hypothalamo-Hypophyseal System; Hypothalamus, Anterior; Lithium Chloride; Male; Morphine; Morphine Dependence; Naloxone; Narcotic Antagonists; Neurosecretion; Oxytocin; Pain Measurement; Pain Threshold; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome

2001